Redx Pharma (LON:REDX) has bolstered its board with the appointment of a former Merck (NYSE:MRK) research and drug development specialist.
Dr Bernhard Kirschbaum, 57, has been added as a non-executive director with immediate effect.
In the eight years to 2013, he worked at US pharma giant Merck/Merck Serono, becoming a member of the board of Merck Serono and executive vice-president of global research & early development.
In his last three years, he grew the company's research and development department, doubling the number of phase II assets in this period.
During his career, he has held roles at Merck/Merck Serono, Sanofi-aventis, Aventis and Hoechst Marion Roussel.
Neil Murray, chief executive of Redx, said: “He has an outstanding track record and I have no doubt that Redx will benefit from his significant commercial and scientific expertise.”
Redx is focused on improving the characteristics of existing drug classes to create what it hopes are highly effective new medicines.